| NCT02855944 | III | Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy) | ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | CO, GA | View Drugs | View Results |
|
|
| NCT03632798 | III | Recurrent ovarian cancer | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Platinum-Resistant or -Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | MS, WV | View Drugs | |
| Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | Approved in Other Cancers | | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | | Liposomal doxorubicin | Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride | Topoisomerase II inhibitor | Approved in Other Cancers | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02584478 | IIa | Recurrent ovarian cancer | A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | CA, FL, LA, TX | View Drugs | View Results |
| Anlotinib | AL3818, Catequentinib | VEGFR2/3 kinase inhibitor | Clinical Trials | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02571725 | II | Recurrent ovarian cancer with germline BRCA1/2 mutations (no prior anti-CTLA-4 mAb) | A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer | FL, NM, OH, VA | View Drugs | View Results |
| Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT01851369 | II | Advanced solid tumors and granulosa cell ovarian cancer (in expansion) | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas | MD | View Drugs | View Results |
| Methoxyamine | TRC102 | Base excision repair inhibitor | Clinical Trials | | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent | Approved in Other Cancers |
|
|
| NCT02873962 | II | Platinum resistant or partially sensitive ovarian cancer | A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | MA | View Drugs | View Results |
| Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02843165 | II | Advanced solid tumors with lesion treatable with radiation therapy | Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease | CA | View Drugs | View Results |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT03651271 | II | Recurrent ovarian cancer with high MSI | An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer | CA, MA, NY, TX | View Drugs | View Results |
| Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03462342 | II | Recurrent ovarian cancer | Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer | PA | View Drugs | View Results |
| Ceralasertib | AZD6738, ATR kinase inhibitor AZD6738 | ATR kinase inhibitor | Clinical Trials | | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03570619 | II | Advanced solid tumors with CDK12 alterations | IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | CA, FL, MD, MI, MO, NY | View Drugs | View Results |
| Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03579316 | II | Recurrent ovarian cancer with progression on or after prior PARP inhibitor | A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP Inhibition | MA, TX | View Drugs | View Results |
| Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | Clinical Trials | | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03610490 | II | Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma | Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types | TX | View Drugs | |
| MDA-TIL | autologous tumor-infiltrating lymphocytes MDA-TIL | Anti-tumor immune response | Clinical Trials |
|
|
| NCT03428802 | II | Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations | A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability | NJ | View Drugs | View Results |
| Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03693014 | II | Advanced solid tumors with limited progression on checkpoint inhibitor treatment | A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade | NJ, NY | View Drugs | View Results |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT03732950 | II | Recurrent ovarian cancer | A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling | CA, MN | View Drugs | View Results |
| Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03734692 | II | Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | PA | View Drugs | |
| Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Rintatolimod | Atvogen | TLR3 agonist and immune cell stimulator | Approved in Other Indications |
|
|
| NCT03673124 | II | Recurrent low grade serous ovarian cancer | A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum | CA, FL, GA, IL, IN, NJ, NM, OH, OK, PA, RI, TX | View Drugs | View Results |
| Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer | | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT03836352 | II | Recurrent ovarian cancer (with tumor lesions < 5 cm) | A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours. | CA, FL, GA, KY, LA, NM, NY, TX | View Drugs | View Results |
| Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | | DPX-Survivac | survivin antigen vaccine DPX-Survivac | Immune response against cancer expressing survivin | Clinical Trials | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03868423 | II | Advanced solid tumors with ALK or ROS1 activating genomic aberrations | Phase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 Oncogenes | OH | View Drugs | View Results |
| Brigatinib | AP26113 | ALK and EGFR kinase inhibitor | Approved in Other Cancers |
|
|
| NCT03878849 | II | Recurrent ovarian cancer | Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® | MA | View Drugs | View Results |
| 2X-121 | PARP/Tankyrase inhibitor 2X-121, E7449 | PARP inhibitor | Clinical Trials |
|
|
| NCT03909152 | II | Recurrent PR+ low grade serous or granulosa cell ovarian cancer | Basket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial Cancer | NJ, NY | View Drugs | View Results |
| Onapristone ER | extended-release onapristone | PR antagonist that blocks PR activation and the associated expression of PR-responsive genes | |
|
|
| NCT03911557 | II | Advanced solid tumors with moderate/high TMB | Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | KY | View Drugs | View Results |
| Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT03907475 | II | Advanced solid tumors (with tumor amenable to skin biopsy) | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination With Chemotherapy in Patients With Advanced Solid Tumors | MD | View Drugs | View Results |
| Capecitabine | Xeloda, CAPE | RNA processing and thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | | Liposomal doxorubicin | Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride | Topoisomerase II inhibitor | Approved in Other Cancers | | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02710253 | II | Advanced solid tumors (amenable to radiation therapy) | Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy | TX | View Drugs | View Results |
| Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT02819843 | II | Advanced solid tumors - intratumoral injection | A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | NJ, NY | View Drugs | |
| Radiation Therapy | Radiotherapy, Irradiation | | | | Talimogene Laherparepvec | GM-CSF-encoding oncolytic herpes simplex virus, T-VEC | Induces immune response and tumor cell lysis | Approved in Other Cancers |
|
|
| NCT03994796 | II | Advanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterations | Genomically-Guided Treatment Trial in Brain Metastases | AK, AR, CA, CO, CT, FL, GA, ID, IL, IA, KY, LA, MA, MI, MN, MS, MO, MT, NE, NJ, NM, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WY | View Drugs | |
| Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | | Entrectinib | TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RXDX-101 | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | | GDC-0084 | RG7666, PI3K inhibitor GDC-0084 | PI3K/mTOR inhibitor | |
|
|
| NCT03993379 | II | Advanced solid tumors | A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors | CA, ID, IL, KY, MA, NY, OR, PA, VA, WA | View Drugs | View Results |
| CX-072 | protease-activated anti-PD-L1 antibody prodrug CX-072 | Blocks PD-L1 inhibition of T cells | Clinical Trials | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04003623 | II | Advanced solid tumors with FGFR mutations or translocations | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208) | CA, FL, HI, IL, MD, NJ, OH, SD, TX, UT | View Drugs | View Results |
| Pemigatinib | INCB054828, FGFR inhibitor INCB054828 | FGFR1-3 inhibitor | Clinical Trials |
|
|
| NCT04034927 | II | Platinum sensitive high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancer | A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer | CA, CT, GA, IL, MO, NM, NY, OH, OK, PA, RI, TX, WI | View Drugs | View Results |
| Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT04083976 | II | Advanced solid tumors with FGFR mutations or gene fusions | A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations | CO, CT, FL, GA, IL, ME, MA, MI, NJ, NY, NC, PA, TN, TX, WA, WI | View Drugs | View Results |
| Erdafitinib | pan-FGFR tyrosine kinase inhibitor JNJ-42756493 | pan-FGFR kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04098068 | II | Advanced solid tumors with high TMB and low MSI | Phase 2 Study of MK-3475 (an Antibody That Blocks Negative Signals to T Cells) in Patients With Microsatellite Unstable (MSI) Tumors | MD, MA, NY, OH, OR, PA | View Drugs | View Results |
| Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04171700 | II | Advanced solid tumors with mutations in BARD1, BRIP1, FANCA, NBN, RAD51, RAD51B, RAD51C or RAD51D | A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes | CA, FL, IA, MA, NY, OK, PA, TN, TX, WA | View Drugs | View Results |
|
|
| NCT04149275 | II | Recurrent carcinosarcoma | Cabozantinib Plus Nivolumab and Ipilimumab Women With Recurrent Gynecologic Carcinosarcoma | AL | View Drugs | View Results |
| Cabozantinib | Cometriq, XL184, Cabometyx, BMS-907351 | Multi-targeted RTK inhibitor | Approved in Ovarian Cancer | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04239014 | II | Recurrent platinum sensitive ovarian cancer with PARP inhibitor maintenance therapy following last platinum-based therapy | A Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance Treatment | Contact research study staff | View Drugs | |
| Ceralasertib | AZD6738, ATR kinase inhibitor AZD6738 | ATR kinase inhibitor | Clinical Trials | | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04042116 | Ib/II | Advanced solid tumors | A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With an Advanced, Metastatic Solid Tumor | FL, OK, TN | View Drugs | View Results |
| Lucitanib | VEGFR/FGFR dual kinase inhibitor E-3810 | VEGFR and FGFR kinase inhibitor | Clinical Trials | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03330405 | Ib/II | Platinum sensitive recurrent ovarian cancer with mutations in ATM or BRCA | A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors | AR, CA, DC, MA, MI, MN, NY, OH, PA, TX | View Drugs | View Results |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Talazoparib | Talazoparib Tosylate, BMN-673, MDV3800 | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT03717415 | Ib/II | Advanced solid tumors | An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors | CA, IL, IN, KS, NC, OH, TN, TX | View Drugs | |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | | Rebastinib | multitargeted tyrosine kinase inhibitor DCC-2036 | Multi-targeted kinase inhibitor | Clinical Trials |
|
|
| NCT03650348 | Ib | Advanced HER2+ solid tumors (inc expansion) | A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors | CA, LA, NY, OH, TX | View Drugs | View Results |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | PRS-343 | anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343 | Directs costimulation of TILs to HER2+ tumor cells | Clinical Trials |
|
|
| NCT02761694 | Ib | Advanced solid tumors with AKT1/2/3, PI3K, or PTEN mutations (in expansion) | A Phase 1b Study of ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN Mutations | OK, SC, TN, TX | View Drugs | View Results |
| ARQ 751 | pan-AKT inhibitor ARQ 751 | Akt inhibitor | Clinical Trials | | Fulvestrant | Faslodex, ICI 182,780, ZD9238 | ER antagonist (SERD) | Approved in Other Cancers | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03589651 | Ib | Advanced solid tumors (inc expansion) | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | CA, CT, FL, IL, NJ, NY, PA, TX | View Drugs | View Results |
| Epacadostat | IDO1 Inhibitor INCB024360, INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, 3-dioxygenase Inhibitor INCB024360 | Inhibits IDO1 to stimulate immune response | Clinical Trials | | MGA012 | INCMGA00012, anti-PD-1 monoclonal antibody MGA012 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials | | Parsaclisib | PI3K-delta inhibitor INCB050465, INCB050465 | PI3K delta inhibitor | Clinical Trials |
|
|
| NCT03318445 | Ib | Advanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion) | Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | CA | View Drugs | |
| Irinotecan | Campothecin-11, Campto, Camptosar | Topoisomerase I inhibitor | NCCN Guidelines for Ovarian Cancer | | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03150810 | Ib | Advanced solid tumors (inc ovarian expansion) | A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors | MI, MO, NY, TN, TX | View Drugs | View Results |
| Pamiparib | PARP inhibitor BGB-290 | PARP inhibitor | Clinical Trials | | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent | Approved in Other Cancers |
|
|
| NCT03206177 | Ib | Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma | Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary | OK | View Drugs | View Results |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | | Galunisertib | LY2157299 | TGFBR1 antagonist | Clinical Trials | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03842228 | Ib | Advanced solid tumors with alterations in ARID1A, ATM, ATRX, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MRE11A, MSH2, PALB2, PARP1, PIK3CA, POLD1, PP2R2A, PTEN, RAD51B, RAD51C, RAD51D, RAD54L or XRCC2 (inc expansion) | A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors | CO, MA, TX | View Drugs | View Results |
| Copanlisib | BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Clinical Trials | | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03872947 | Ib | Platinum sensitive or partially sensitive ovarian cancer with no prior gemcitabine | A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors | AZ, CA, LA, NJ, WI | View Drugs | |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | TRK-950 | monoclonal antibody TRK-950 | Undisclosed mechanism | Clinical Trials |
|
|
| NCT03695380 | Ib | Platinum sensitive ovarian cancer with ≤ 2 prior platinum therapies (in expansion) | A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer | AZ, CA, FL, GA, MD, MO, NY, OK, TN, WI | View Drugs | View Results |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Cobimetinib | XL518, GDC-0973, Cotellic | MEK1 inhibitor | Approved in Other Cancers | | Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04244552 | Ib | Advanced solid tumors | A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults With Advanced Solid Malignancies | NC | View Drugs | |
| ATRC-101 | | Anti-tumor immune response | Clinical Trials |
|
|
| NCT04332653 | Ib | Advanced solid tumors | An Open-label Phase 1b/2a Study of NT-I7 (Hyleukin-7) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors | Contact research study staff | View Drugs | View Results |
| NT-I7 | recombinant human IL-7-hybrid Fc NT-I7, Hyleukin, GX-I7 | IL-7R agonist | Clinical Trials | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03209401 | Ia/Ib | Advanced solid tumors with mutations in ARID1A, ATM, ATRX, BAP1, BARD1, BLM, BRCA1/2, BRIP1, CHEK1, CHEK2, FAM175A, FANCA/C/D2/E/F/G/L, MLL2, MRE11A, NBN, PALPB2, PTEN, RAD50/51/51B, SLX4, WRN, or XRCC (inc expansion) | Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies | DC, NJ, NC | View Drugs | |
|
|
| NCT03110107 | I/IIa | Advanced solid tumors | Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors | CO, MA, NV, NJ, NY, PA, SD | View Drugs | |
| BMS-986218 | | Blocks CTLA-4 inhibition of T cells | Clinical Trials | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02754141 | I/IIa | Advanced solid tumors | A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors | CT, IL, MD, MA, NY, OK, PA, TN, TX | View Drugs | View Results |
| BMS-986179 | anti-CD73 monoclonal antibody BMS-986179 | Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells | Clinical Trials | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02650986 | I/IIa | Advanced solid tumors | A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies | NY | View Drugs | |
| Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | | NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL | anti-NY-ESO-1 TCR gene-engineered lymphocytes | Immune response against cancer expressing NY-ESO-1 | Clinical Trials | | TGFbeta DNRII-transduced Autologous Tumor Infiltrating Lymphocytes | TGFbeta Dominant Negative Receptor II transduced TILS | TGFbeta ligand trap, Anti-tumor immune response enhanced by TGFbeta inhibition | Clinical Trials |
|
|
| NCT04219254 | I/IIa | Advanced solid tumors with prior anti-PD-1/PD-L1 Ab | A Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Previously Treated With Anti-PD-1 or Anti-PD-L1 Antibodies | CO, MI, MN, OK, TX | View Drugs | |
| BI-1206 | anti-CD32B monoclonal antibody BI-1206, anti-hFcγRIIB monoclonal antibody BI-1206 | Blocks CD32B inhibition of immune cells | Clinical Trials | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03973333 | I/II | Advanced MAGE-A4+ solid tumors | A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer | CA, IL, NY, PA, TN, TX | View Drugs | |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | IMC-C103C | IMC-C103C, a T cell redirecting bi-specific biologic | Re-directs T cells to attack MAGE-A4+ tumor cells | Clinical Trials |
|
|
| NCT04205227 | I/II | Advanced ETBR+ solid tumors | A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Contact research study staff | View Drugs | |
| ENB003 | | ETBR antagonist | Clinical Trials | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03515551 | I/II | Advanced NY-ESO-1+/LAGE-1+ solid tumors | A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer | CO, FL, IA, MI, MO, NY, PA, TN, TX, UT | View Drugs | |
| IMCnyeso | GSK01, anti-NY-ESO1/LAGE-1A TCR/scFv anti-CD3 IMCnyeso | Re-directs T cells to attack NY-ESO-1+/LAGE-1+ tumor cells | Clinical Trials |
|
|
| NCT04266912 | I/II | Advanced solid tumors with alterations in ARID1A, ATM, ATR, ATRX, BAP1, BARD1, BRCA1/2, BRIP1, CDK12, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCM, MRE11A, MSH2, NBN (NBS1), PALB2, RAD51, RAD51C, RAD51D, SMARCB1 or VHL | DNA Damage Repair (DDR) Inhibitor-Based Basket of Baskets Trial in Patients With Advanced Solid Tumors Harboring Aberrations In DDR Genes (D-BoB) | TX | View Drugs | View Results |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Berzosertib | ATR kinase inhibitor VX-970, VE-822, M6620, VX-970 | ATR kinase inhibitor | Clinical Trials | | Nedisertib | M3814, DNA-PK inhibitor MSC2490484A, Peposertib | DNA-PK inhibitor | Clinical Trials |
|
|
| NCT04009681 | I/II | Advanced solid tumors | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in Combination With a Checkpoint Inhibitor in Adult Subjects With Advanced or Metastatic Solid Tumors | CO, FL, TN, TX | View Drugs | |
| PD-1i | | Blocks PD-L1/2 inhibition of T cells | | | THOR-707 | pegylated recombinant interleukin-2 THOR-707 | IL-2 receptor beta and gamma agonist | Clinical Trials |
|
|
| NCT04317105 | I/II | Advanced solid tumors (inc expansion) | A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumors | Contact research study staff | View Drugs | View Results |
| Copanlisib | BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Clinical Trials | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02111850 | I/II | Advanced MAGE-3+ solid tumors | Phase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin | MD | View Drugs | View Results |
| Aldesleukin | | IL-2 receptor agonist | Approved in Other Cancers | | Anti-MAGE-A3-DP4 TCR PBL | HLA-DP0401/0402-restricted, MAGE-A3-reactive T cell receptor-transduced autologous T cells | Immune response against cancer expressing MAGE-3 | Clinical Trials | | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers |
|
|
| NCT02953457 | I/II | Recurrent, persistent or refractory high grade serous ovarian cancer with BRCA1/2 or HRD or MMR gene alterations or LOH high score | A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation | NY | View Drugs | View Results |
| Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT02671435 | I/II | Advanced solid tumors | A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors | AL, AZ, CA, CO, FL, IL, MD, MA, MI, NJ, NY, PA, RI, TN, TX, UT, WA | View Drugs | View Results |
| Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Monalizumab | anti-NKG2A monoclonal antibody IPH2201, IPH2201 | Blocks HLA-E inhibition of NKG2A+ NK and cytotoxic T-lymphocytes | Clinical Trials |
|
|
| NCT02432378 | I/II | Platinum sensitive ovarian cancer with first recurrence in peritoneal cavity - intranodal injection | A Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 Vaccines | PA | View Drugs | |
| Alpha-DC1 vaccine | | Immune response against tumor-associated antigens | Clinical Trials | | Celecoxib | Celebrex | | Approved in Other Indications | | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | | Rintatolimod | Atvogen | TLR3 agonist and immune cell stimulator | Approved in Other Indications |
|
|
| NCT02734004 | I/II | Platinum sensitive recurrent ovarian cancer | A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors | GA, MD, MA, MI, MO, OH, PA | View Drugs | View Results |
| Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02484404 | I/II | Recurrent ovarian cancer | Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | MD | View Drugs | View Results |
| Cediranib | AZD2171, Cediranib maleate, Recentin | VEGFR1-3 kinase inhibitor | Clinical Trials | | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02487095 | I/II | Extrapulmonary small cell ovarian cancer | A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers | MD | View Drugs | View Results |
| Berzosertib | ATR kinase inhibitor VX-970, VE-822, M6620, VX-970 | ATR kinase inhibitor | Clinical Trials | | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03314935 | I/II | Advanced solid tumors | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | AL, CA, GA, TX | View Drugs | View Results |
| Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | | INCB001158 | CB-1158, Arginase inhibitor | Arginase inhibitor | Clinical Trials | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03369223 | I/II | Advanced solid tumors | A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | CO, FL, MD, NJ, NY, OH, OR, PA, SC, TX, VA, WA | View Drugs | |
| BMS-986249 | Probody of ipilumumab | Blocks CTLA-4 inhibition of T cells | Clinical Trials | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03386526 | I/II | Advanced solid tumors | A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies | TX | View Drugs | View Results |
| APG-1387 | | SMAC mimetic and IAP antagonist | Clinical Trials | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03157128 | I/II | Advanced solid tumors with RET alterations | A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) | AZ, CA, CO, CT, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WI | View Drugs | View Results |
| Selpercatinib | RET kinase inhibitor LOXO-292, LOXO-292 | RET-kinase inhibitor | Clinical Trials |
|
|
| NCT03665285 | I/II | Recurrent ovarian cancer | A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | CA, CT, NJ, NY, TX | View Drugs | View Results |
| NC318 | anti-S15 monoclonal antibody NC318, anti-Siglec-15 monoclonal antibody NC318 | Blocks tumor-associated macrophage stimulation of tumor growth | Clinical Trials |
|
|
| NCT03721679 | I/II | Advanced solid cancers | Poly-ICLC (Hiltonol®) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot Study | MD, NY | View Drugs | View Results |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Cemiplimab | REGN2810, anti-PD-1 monoclonal antibody REGN2810 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | poly ICLC | poly-ICLC, Hiltonol, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, poly I:poly C with poly-1-lysine stabilizer | Activates dendritic cells and induces interferon production | Clinical Trials |
|
|
| NCT03761914 | I/II | Recurrent or persistent WT1+ ovarian cancer | A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers | CA, CO, FL, NJ, NY, OH, TX, VA | View Drugs | View Results |
| Galinpepimut-S | SLS 001, WT-1 analog peptide vaccine SLS-001 | Immune response against cancer expressing WT1 | Clinical Trials | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03744468 | I/II | Advanced solid tumors | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | CO, PA | View Drugs | |
| BGB-A425 | | Blocks TIM-3 inhibition of T cells | Clinical Trials | | Tislelizumab | anti-PD-1 monoclonal antibody BGB-A317 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials |
|
|
| NCT03767348 | I/II | Advanced solid tumor - intratumoral injection | An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors | AL, AZ, CA, CT, FL, IA, KY, NJ, NY, OR, TN, TX, UT, WA, WI | View Drugs | |
| Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | RP1 | oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT03840200 | I/II | Recurrent ovarian cancer | A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer | CA, NJ, PA, TX | View Drugs | View Results |
| Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03907852 | I/II | Advanced mesothelin+ solid tumors | A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer | MD, NY, PA, TN, TX | View Drugs | |
| Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | | TC-210 T cells | TC-210 TruC-T cells | Immune response against cancer expressing mesothelin | Clinical Trials |
|
|
| NCT03992131 | I/II | Advanced solid tumors | SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor | MA, TN, TX | View Drugs | View Results |
| Lucitanib | VEGFR/FGFR dual kinase inhibitor E-3810 | VEGFR and FGFR kinase inhibitor | Clinical Trials | | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03994601 | I/II | Advanced solid tumors | A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant Tumors | CO, MD, MO, NJ | View Drugs | |
| BMS-986288 | | Undisclosed mechanism | Clinical Trials | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04021043 | I/II | Advanced solid tumors | Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies | TX | View Drugs | View Results |
| BMS-986156 | | GITR (glucocorticoid-induced TNFR) agonist | Clinical Trials | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT03997968 | I/II | Advanced solid tumors | A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors | CO, FL, NJ, PA, TN, TX, WA, WI | View Drugs | |
|
|
| NCT03138083 | I/II | Advanced solid tumors with MET alterations | A Modular, Multi-arm, Multi-part, First Time in Patient Study to Evaluate the Safety and Tolerability of OMO-1, Alone and in Combination With Anti-cancer Treatments, in Patients With Locally Advanced, Unresectable or Metastatic Solid Malignancies | TX | View Drugs | View Results |
| OMO-1 | JNJ-38877618, MET kinase inhibitor OMO-1 | c-Met kinase inhibitor | |
|
|
| NCT04104776 | I/II | Advanced solid tumors | A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination With Other Therapy in Patients With Advanced Solid Tumors | MI, NJ, TX | View Drugs | |
| CPI-0209 | | EZH2 histone methyltransferase inhibitor | | | Irinotecan | Campothecin-11, Campto, Camptosar | Topoisomerase I inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT03785249 | I/II | Advanced solid tumors with KRAS G12C mutations | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation | CA, CO, MA, MI, NY, NC, TN, TX, VA, WI | View Drugs | View Results |
| MRTX849 | KRAS G12C inhibitor MRTX849 | KRAS G12C inhibitor | Clinical Trials |
|
|
| NCT03729596 | I/II | Advanced solid tumors | A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors | MI, NC, VA | View Drugs | |
| MGA012 | INCMGA00012, anti-PD-1 monoclonal antibody MGA012 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials | | MGC018 | A humanized anti-B7-H3 antibody conjugated to the vc- seco - DUocarmycin-hydroxyBenzamide-Azaindole (DUBA) 2 DNA alkylating payload | ADC: anti-B7-H3 + DNA alkylating agent (duocarmycin) | Clinical Trials |
|
|
| NCT04068194 | I/II | Advanced solid tumors | A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | CA, NJ | View Drugs | View Results |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Nedisertib | M3814, DNA-PK inhibitor MSC2490484A, Peposertib | DNA-PK inhibitor | Clinical Trials | | Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT04143711 | I/II | Advanced HER2+ solid tumors | A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications | RI, TX | View Drugs | |
| DF1001 | | Activates NK cells to stimulate immune response | | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03907969 | I/II | Advanced solid tumors | A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced Malignancies | CT, TX | View Drugs | |
| AZD7648 | | DNA-PK inhibitor | | | Liposomal doxorubicin | Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride | Topoisomerase II inhibitor | Approved in Other Cancers | | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03600883 | I/II | Advanced solid tumors with KRAS G12C mutations | A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) | CA, CO, CT, FL, GA, IN, MA, MI, MO, NY, NC, PA, SC, TN, TX, UT, VA, WA | View Drugs | View Results |
| AMG 510 | KRAS mutant-targeting AMG 510 | KRAS G12C inhibitor | Clinical Trials |
|
|
| NCT03297424 | I/II | Advanced solid tumors | A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies | AZ, FL, NY, TX, VA | View Drugs | |
| PLX2853 | BRD4 inhibitor PLX2853 | BRD4 inhibitor | |
|
|
| NCT04165330 | I/II | Advanced solid tumors | A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 (Catequentinib) to Nivolumab in Solid Tumors | CA | View Drugs | View Results |
| Anlotinib | AL3818, Catequentinib | VEGFR2/3 kinase inhibitor | Clinical Trials | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04165031 | I/II | Advanced solid tumors with KRASG12C mutation | A Phase 1/2 Study of LY3499446 Administered to Patients With Advanced Solid Tumors With KRAS G12C Mutation | CA, IL, IN, MA, NH, NJ, NY, NC, OK, TN, TX, WA | View Drugs | |
| Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | | Cetuximab | Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225 | EGFR antagonist | Approved in Other Cancers | | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | Approved in Other Cancers | | Erlotinib | Tarceva | EGFR kinase inhibitor | | | LY3499446 | | KRAS G12C inhibitor | |
|
|
| NCT02660034 | I/Ib | Platinum sensitive or partially sensitive ovarian cancer (at least 2 prior platinum therapies, in expansion) | A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors | AZ, CA, FL, MA, TN, TX, VA | View Drugs | View Results |
| Pamiparib | PARP inhibitor BGB-290 | PARP inhibitor | Clinical Trials | | Tislelizumab | anti-PD-1 monoclonal antibody BGB-A317 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials |
|
|
| NCT01417546 | I | Advanced solid tumors (in expansion) | First In-Human Phase I Trial of NHS-IL12 in Patients With Metastatic Solid Tumors | MD | View Drugs | View Results |
| NHS-IL12 | immunocytokine NHS-IL12, M9241 | IL-12 receptor agonist | Clinical Trials |
|
|
| NCT03435250 | I | Advanced solid tumors with CDKN2A deletion (inc expansion) | A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAP | CT, MA, NY, TN | View Drugs | View Results |
| AG-270 | | Methionine adenosyltransferase 2a (MAT2A) inhibitor | Clinical Trials |
|
|
| NCT03255070 | I | Advanced HER+ solid tumors | A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression | MO | View Drugs | |
| ARX788 | anti-HER2 antibody-drug conjugate ARX788, ADC ARX788 | ADC: anti-HER2 + microtubule destabilizer (MMAF) | Clinical Trials |
|
|
| NCT03330561 | I | Advanced HER2+ solid tumors (inc expansion) | A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors | AZ, CA, DC, MD, NY, PA, TN, TX | View Drugs | View Results |
| PRS-343 | anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343 | Directs costimulation of TILs to HER2+ tumor cells | Clinical Trials |
|
|
| NCT03059823 | I | Advanced solid tumors (in expansion) | A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors | AZ, MI, NJ, NC, TX, VA | View Drugs | View Results |
| MGA012 | INCMGA00012, anti-PD-1 monoclonal antibody MGA012 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials |
|
|
| NCT03431948 | I | Advanced solid tumors (amenable to radiation therapy) | Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors | IL | View Drugs | View Results |
| Cabiralizumab | anti-CSF1R monoclonal antibody FPA008, FPA008 | CSF1R antagonist and tumor-associated macrophage inhibitor | Clinical Trials | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Radiation Therapy | Radiotherapy, Irradiation | | | | Urelumab | BMS-663513, anti-CD137 monoclonal antibody, anti-4-1BB monoclonal antibody | Stimulates 4-1BB (CD137) to increase T cells and immune response | Clinical Trials |
|
|
| NCT03335540 | I | Advanced solid tumors | ADaptiVe Biomarker Trial That InformS Evolution of Therapy | IL, MD, PA | View Drugs | |
| BMS-986205 | | Inhibits IDO1 to stimulate immune response | Clinical Trials | | Cabiralizumab | anti-CSF1R monoclonal antibody FPA008, FPA008 | CSF1R antagonist and tumor-associated macrophage inhibitor | Clinical Trials | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Relatlimab | BMS986016, Anti-LAG-3 monoclonal antibody BMS-986016, Anti-LAG-3 monoclonal antibody BMS-986016 | Blocks LAG-3 inhibition of T cells | Clinical Trials |
|
|
| NCT03144661 | I | Recurrent ovarian cancer | A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | AL, NY, OH | View Drugs | |
| INCB062079 | | FGFR4 inhibitor | Clinical Trials |
|
|
| NCT03154294 | I | Advanced solid tumors | A Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid Tumors | SD | View Drugs | View Results |
| Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | | Sapanisertib | TAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128 | TORC1/2 kinase inhibitor | Clinical Trials | | Serabelisib | PI3K alpha inhibitor MLN1117, TAK-117, INK-1117, MLN1117 | PI3K alpha inhibitor | Clinical Trials |
|
|
| NCT03213964 | I | Recurrent advanced ovarian cancer only in abdomen/pelvis | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2 in Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | MN | View Drugs | View Results |
| FATE-NK100 | NKG2C/CD57-expressing adaptive memory natural killer cells FATE-NK100 | Anti-tumor immune response | Clinical Trials |
|
|
| NCT03724890 | I | Advanced solid tumors | A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid Tumors | CA, FL, IL, NY, OH, OK, PA, SC, TN | View Drugs | View Results |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Nedisertib | M3814, DNA-PK inhibitor MSC2490484A, Peposertib | DNA-PK inhibitor | Clinical Trials | | Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT03725436 | I | Advanced solid tumors that are TP53 WT | A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast Cancer | TX | View Drugs | View Results |
| ALRN-6924 | MDM2/MDMX inhibitor ALRN-6924 | MDM2 and MDMX inhibitor | Clinical Trials | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03691376 | I | Recurrent or refractory NY-ESO-1+ ovarian cancer | A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NY | View Drugs | |
| Aldesleukin | | IL-2 receptor agonist | Approved in Other Cancers | | Melphalan | Sarcolysin, Alkeran, Alkerana, Melfalan, Phenylalanine mustard | DNA damaging agent | Approved in Other Cancers | | NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) | | Immune response against cancer expressing NY-ESO-1 | Clinical Trials | | NY-ESO-1 CD8-TCR Engineered T Cells | | Immune response against cancer expressing NY-ESO-1 | Clinical Trials |
|
|
| NCT03502733 | I | Advanced solid tumors (in expansion) | Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas | MD, TX | View Drugs | View Results |
| Copanlisib | BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Clinical Trials | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03585764 | I | Recurrent or persistent FRalpha+ high grade serous ovarian cancer | Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | PA | View Drugs | |
| Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | | MOv19-BBz CAR T | | Immune response against cancer expressing folate receptor | Clinical Trials |
|
|
| NCT03486301 | I | Advanced solid tumors (inc expansion) | Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | FL, TN, TX | View Drugs | |
| BDB001 | | TLR agonist and immune cell stimulator | Clinical Trials | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT01434316 | I | Advanced solid tumors including those with BRCA1/2 mutations (in expansion) | Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors | MA | View Drugs | View Results |
| Dinaciclib | CDK inhibitor SCH 727965, SCH 727965 | CDK1, 2, 5, 9 inhibitor | Clinical Trials | | Veliparib | ABT-888 | PARP inhibitor | Clinical Trials |
|
|
| NCT02269293 | I | Advanced ovarian cancer at first recurrence | A Phase 1 Open-label Study of the Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | NJ, NY | View Drugs | View Results |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | | Selinexor | KPT-330, CRM1 nuclear export inhibitor KPT-330, selective inhibitor of nuclear export KPT-330 | Selective inhibition of nuclear export (SINE) | Approved in Other Cancers |
|
|
| NCT02627443 | I | Platinum sensitive ovarian cancer at first or second recurrence | Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer | AZ, CO, FL, KY, MI, MN, NJ, PA, VA | View Drugs | View Results |
| Berzosertib | ATR kinase inhibitor VX-970, VE-822, M6620, VX-970 | ATR kinase inhibitor | Clinical Trials | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02433626 | I | Recurrent ovarian cancer | A Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent Malignancies | TX | View Drugs | View Results |
| Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | | COTI-2 | mutant p53 activator COTI-2 | Mutant p53 activator | Clinical Trials |
|
|
| NCT01376505 | I | Advanced solid tumors (in ovarian expansion) | Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors | OH | View Drugs | View Results |
| MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccine | B-Vaxx | Immune response against cancer expressing HER2 | Clinical Trials |
|
|
| NCT02791334 | I | Advanced solid tumors (in expansion) | A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT) | TN, TX | View Drugs | View Results |
| Lodapolimab | LY3300054 | Blocks PD-L1 inhibition of T cells | Clinical Trials | | LY3321367 | anti-TIM3 monoclonal antibody LY3321367 | Blocks TIM-3 inhibition of T cells | Clinical Trials | | Ramucirumab | anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, IMC-1121B, LY3009806 | VEGFR2 antagonist | Approved in Other Cancers |
|
|
| NCT02897375 | I | Advanced solid tumors | A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies | GA | View Drugs | View Results |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT02498912 | I | MUC16ecto+ recurrent high grade serous ovarian cancer (> 2 prior therapies) | A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors | NY | View Drugs | |
| 4H11-28z/fIL-12/EFGRt-expressing autologous T lymphocytes | autologous MUC16ecto-targeting EGFR-secreting T lymphocytes, 4H11-28z/fIL-12/EFGRt+ genetically-modified T cells | Immune response against cancer expressing MUC16ecto | Clinical Trials | | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers |
|
|
| NCT03017131 | I | Recurrent or refractory ovarian cancer | A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian Cancer | NY | View Drugs | |
| Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | | Decitabine | dezocitidine, deoxyazacytidine, 5-aza-dCyd, Dacogen | DNA methylation inhibitor | Approved in Other Cancers | | Genetically Engineered NY-ESO-1-specific T Lymphocytes | | Immune response against cancer expressing NY-ESO-1 | Clinical Trials |
|
|
| NCT03030378 | I | Advanced solid tumors | A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors | CA, CO, CT, FL, MD, MA, OH, PA, VA | View Drugs | View Results |
| IL-12 | Edodekin alfa, cytotoxic lymphocyte maturation factor interleukin-12, Ro 24-7472, recombinant interleukin-12, natural killer cell stimulatory factor NM-IL-12 | IL-12 receptor agonist | | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02972034 | I | Advanced solid tumors | A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in Combination With Pembrolizumab in Patients With Advanced Malignancies | MI, TN | View Drugs | View Results |
| MK-8353 | ERK1 inhibitor MK-8353 | ERK inhibitor | Clinical Trials | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02611024 | I | Advanced solid tumors (inc expansion) | Phase I, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors | MA | View Drugs | View Results |
| Irinotecan | Campothecin-11, Campto, Camptosar | Topoisomerase I inhibitor | NCCN Guidelines for Ovarian Cancer | | Lurbinectedin | PM01183 | DNA damaging agent | Clinical Trials |
|
|
| NCT03056833 | I | Platinum sensitive recurrent ovarian cancer | Phase I Trial of Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer | PA | View Drugs | View Results |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT03023319 | I | Advanced solid tumors | Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | GA | View Drugs | |
| Bosutinib | Bosulif, SKI-606 | Abl and src family kinase inhibitor | Approved in Other Cancers | | Pemetrexed | Pemetrexed disodium, Alimta | DHFR and Thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT03069469 | I | Advanced solid tumors (in expansion) | Multi-center, Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors | CA, CO, FL, NY, OR, TN | View Drugs | View Results |
| DCC-3014 | | CSF1R kinase inhibitor | Clinical Trials |
|
|
| NCT03054298 | I | Recurrent or persistent mesothelin+ serous ovarian cancer | Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers | PA | View Drugs | |
| Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | | Hu-CART-meso cells | | Immune response against cancer expressing mesothelin | Clinical Trials |
|
|
| NCT03154281 | I | Advanced ovarian cancer (no prior PARPi) | A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Ovarian and Breast Cancer | SD | View Drugs | |
| Everolimus | Afinitor, Certican, RAD001, Zortress | mTOR inhibitor | Approved in Other Cancers | | Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03310541 | I | Advanced solid tumors with AKT1, AKT2, or AKT3 mutations | A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3 | NJ, NY | View Drugs | View Results |
| Capivasertib | Akt inhibitor AZD5363, AZD5363 | pan-AKT inhibitor | Clinical Trials |
|
|
| NCT03313778 | I | Advanced solid tumors with high MSI or high TMB (in expansion) | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors | AZ, FL, MA, NJ, NY, NC, TN | View Drugs | View Results |
| mRNA-4157 | mRNA-based personalized cancer vaccine mRNA-4157 | Immune response against tumor-associated antigens | Clinical Trials | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03229278 | I | Advanced solid tumors with high MSI | A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies | NJ | View Drugs | View Results |
| Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Trigriluzole | BHV-4157, FC-4157 | Glutamate antagonist | Clinical Trials |
|
|
| NCT04149145 | I | Recurrent ovarian cancer with progression on prior PARP inhibitor (inc expansion) | Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian Cancer | AL | View Drugs | View Results |
|
|
| NCT04130542 | I | Advanced solid tumors (inc expansion) | An Open Label, First in Human (FIH), Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy | TX | View Drugs | |
| LVGN6051 | | Stimulates 4-1BB (CD137) to increase T cells and immune response | | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04134312 | I | Advanced solid tumors | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | MD | View Drugs | |
| MVA-BN-brachyury | brachyury-expressing modified vaccinia Ankara-TRICOM vaccine | Immune response against cancer expressing brachyury | Clinical Trials |
|
|
| NCT04087018 | I | Advanced solid tumors with high TMB or positive Strata Immune Signature | A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants With Advanced Solid Tumors | AL, CA, DE, KY, LA, MD, MN, OH, PA, SC, TX, WA, WI | View Drugs | View Results |
| AB122 | anti-PD-1 monoclonal antibody AB122 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials |
|
|
| NCT04088786 | I | Patients with peritoneal disease who are candidates for grossly complete cytoreduction surgery | Phase I Trial of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy With Nanoliposomal Irinotecan in Patients With Peritoneal Surface Malignancies | CA, KY, NY | View Drugs | |
| Liposomal irinotecan | Onivyde, MM-398, liposome-encapsulated irinotecan hydrochloride PEP02, nal-IRI, nanoliposomal irinotecan | Topoisomerase I inhibitor | |
|
|
| NCT04092270 | I | Recurrent ovarian cancer (inc expansion) | A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With M3814 in Ovarian Cancer With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) | Contact NCI | View Drugs | View Results |
| Liposomal doxorubicin | Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride | Topoisomerase II inhibitor | Approved in Other Cancers | | Nedisertib | M3814, DNA-PK inhibitor MSC2490484A, Peposertib | DNA-PK inhibitor | Clinical Trials |
|
|
| NCT04095273 | I | Advanced solid tumors DNA Damage Repair pathway alterations (inc ovarian expansion) | A Multicenter, Non-randomized, Open-label Phase 1b Study to Determine the Maximum Tolerated and Recommended Phase 2 Dose of the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients With Advanced Solid Tumors | CA, CT, MD, OH, TX | View Drugs | View Results |
| BAY1895344 | ATR kinase inhibitor BAY1895344 | ATR kinase inhibitor | Clinical Trials | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04007744 | I | Advanced solid tumors with high MSI | A Phase 1 Trial of Sonidegib and Pembrolizumab in Advanced Solid Tumors | AZ, FL, MN | View Drugs | View Results |
| Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Sonidegib | LDE225, Smoothened Antagonist LDE225, Erismodegib, Odomzo | Smoothened antagonist | Approved in Other Cancers |
|
|
| NCT04034238 | I | Advanced mesothelin+ solid tumors | A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | MD | View Drugs | View Results |
| LMB-100 | anti-mesothelin recombinant cytolytic fusion protein RO6927005, anti-mesothelin cytolytic fusion protein LMB-100 | ADC: anti-mesothelin + Pseudomonas exotoxin (PE) | Clinical Trials | | Tofacitinib | Tasocitinib, CP-690550 | JAK kinase inhibitor | Approved in Other Indications |
|
|
| NCT04053673 | I | Advanced solid tumors (inc expansion) | A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors | CO, FL, TN, TX | View Drugs | |
| RBN-2397 | | PARP7 inhibitor | Clinical Trials |
|
|
| NCT03416335 | I | Advanced solid tumors | A First-in-Human Phase 1/2 Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, Administered as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | IN, NC, PA, TN, TX | View Drugs | |
| DSP-0509 | toll-like receptor 7 agonist DSP-0509 | TLR7 agonist and immune cell activator | Clinical Trials | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03968406 | I | Recurrent ovarian cancer (amenable to radiation therapy) - without ascites | Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers | TX | View Drugs | View Results |
| Radiation Therapy | Radiotherapy, Irradiation | | | | Talazoparib | Talazoparib Tosylate, BMN-673, MDV3800 | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT03970382 | I | Advanced solid tumors (inc expansion) | A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors | CA | View Drugs | |
| NeoTCR-P1 | gene-edited autologous neoantigen-targeted NeoTCR-P1 T cells | Immune response against tumor-associated antigens | Clinical Trials | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03219268 | I | Advanced solid tumors, including HER2+ cohort (in ovarian expansion) | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms | AZ, CA, FL, IL, MD, MA, NC, OH, OK, PA, TN, TX | View Drugs | |
| Margetuximab | anti-HER2 mAb MGAH22, anti-HER2/c-erbB2 monoclonal antibody | HER2 antagonist | | | MGD013 | dual-affinity retargeting protein MGD013, anti-PD-1/anti-LAG-3 DART protein MGD013 | Blocks LAG-3 and PD-1 inhibition of T cells | Clinical Trials |
|
|
| NCT03363893 | I | Advanced solid tumors (inc expansion) | A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies | NY | View Drugs | |
| CT7001 | CDK7 inhibitor CT7001 | CDK7 inihibitor | Clinical Trials |
|
|
| NCT03841110 | I | Advanced solid tumors (inc expansion) | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1) | CA, MN, TX | View Drugs | |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | | FT500 | | Anti-tumor immune response | Clinical Trials | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03849469 | I | Advanced solid tumors (inc expansion) | A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4) | CA, GA, MA, MI, MO, NY, PA, TX, UT | View Drugs | |
| Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | | XmAb22841 | anti-CTLA-4/LAG-3 bispecific antibody XmAb22841 | Blocks LAG-3 and CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT03861793 | I | Advanced solid tumors (inc expansion) | A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001) | DC, GA, MI, NY, NC, PA | View Drugs | View Results |
| ALKS 4230 | intermediate-affinity interleukin-2 receptor agonist ALKS 4230 | IL-2 receptor agonist | Clinical Trials | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03556228 | I | Advanced solid tumors (inc expansion) | An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma | CA, NJ, WI | View Drugs | |
| VMD-928 | TrkA inhibitor VMD-928 | TRK kinase inhibitor | Clinical Trials |
|
|
| NCT03831295 | I | Advanced solid tumors - intratumoral injection | Intratumoral Injection of SD-101, an Immunostimulatory CpG Oligonucleotide, in Combination With BMS- 986178, an OX40 Agonist Antibody, in Advanced Solid Malignancies [CA012-014] | CA | View Drugs | |
| BMS-986178 | anti-OX40 antibody BMS 986178 | Stimulates OX40 to increase T cell activation and immune response | Clinical Trials | | SD-101 | TLR9 agonist SD-101, ISS-ODN SD-101 | TLR9 agonist and immune cell activator | Clinical Trials |
|
|
| NCT03748186 | I | Recurrent ovarian cancer (inc expansion) | A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate (ADC) in Advanced Epithelial Ovarian Cancer and Endometrial Cancers | CO, FL, IL, NV, NC, OH, PA, TN, WI | View Drugs | View Results |
| STRO-002 | | ADC: anti-FOLR1 + microtubule destabilizer (SC209) | Clinical Trials |
|
|
| NCT03139370 | I |
